Quick Answer
Inhibitor Therapeutics, Inc. reported Net Income Loss of -$3.30 million for the year ending 2025.
- Inhibitor Therapeutics, Inc. showed an increase of +1.2% in Net Income Loss from 2024 to 2025.
- This data is from Inhibitor Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: -$266.9 thousand | Q3 2013: -$1.29 million | Q1 2014: -$196.5 thousand | Q2 2014: -$2.14 million | Q3 2014: -$740.1 thousand | Q1 2015: -$922.7 thousand | Q2 2015: -$791.7 thousand | Q3 2015: -$1.20 million | Q1 2016: -$1.19 million | Q2 2016: -$1.33 million | Q3 2016: -$1.73 million | Q1 2017: -$2.80 million | Q2 2017: -$716.4 thousand | Q3 2017: -$679.1 thousand | Q1 2018: -$1.17 million | Q2 2018: -$881.9 thousand | Q3 2018: -$1.17 million | Q1 2019: -$786.3 thousand | Q2 2019: -$632.7 thousand | Q3 2019: -$678.5 thousand | Q1 2020: -$384.4 thousand | Q2 2020: -$314.9 thousand | Q3 2020: -$302.8 thousand | Q1 2021: -$127.8 thousand | Q2 2021: -$66.2 thousand | Q3 2021: -$71.1 thousand | Q1 2022: -$98.9 thousand | Q2 2022: -$77.6 thousand | Q3 2022: -$77.7 thousand | Q1 2023: -$539.6 thousand | Q2 2023: -$654.5 thousand | Q3 2023: -$664.8 thousand | Q1 2024: -$684.7 thousand | Q2 2024: -$501.7 thousand | Q3 2024: -$731.0 thousand | Q1 2025: -$632.8 thousand | Q2 2025: -$659.9 thousand | Q3 2025: -$712.2 thousand.
- Over the full 14 years of available data (2012 to 2025), Inhibitor Therapeutics, Inc.'s Net Income Loss has declined by 1,870.9%.
- Historical annual values: Fiscal year 2025: -$3.30 million | Fiscal year 2024: -$3.34 million | Fiscal year 2023: -$3.03 million | Fiscal year 2022: $12.11 million | Fiscal year 2021: -$298.6 thousand | Fiscal year 2020: -$1.06 million | Fiscal year 2019: -$2.73 million | Fiscal year 2018: -$4.55 million | Fiscal year 2017: -$5.10 million | Fiscal year 2016: -$7.00 million | Fiscal year 2015: -$3.95 million | Fiscal year 2014: -$3.98 million | Fiscal year 2013: -$1.84 million | Fiscal year 2012: $186.4 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: